OLBA HEALTHCARE HOLDINGS,Inc. Q4 FY2025 earnings call

• Corporate Purpose

  • The company's purpose is to contribute to the development of medicine, medical care and nursing through business, and to support the healthy longevity of the public. All employees share the mission of "contributing as a regional medical infrastructure" and "never stopping medical and nursing care".

• Overall 2025 June Fiscal Year Performance

  • The company achieved 5 consecutive years of revenue growth, with a full-year consolidated revenue of 122.702 billion yen (a new all-time high), operating profit of 1.979 billion yen (down 248 million yen YoY), and net profit attributable to parent company shareholders of 1.43 billion yen. The profit decline was driven by weak capital equipment sales and increased SG&A from company-wide base salary increases, human capital investment, and system investments for future growth.

• Core Business Expansion

  • In the medical equipment business, the Kobe sales office was upgraded to the Kansai Branch, driving orthopedic consumables revenue in the region up 10.6% YoY; all consumables categories grew YoY, while capital equipment sales declined due to weakened hospital capital investment. For SPD business, the company plans to open a new center in Shikoku, expand existing centers, and push sales of its self-developed in-house inventory management system "Media" for small and medium-sized hospitals. For nursing care products business, the company opened a new sales office in Kochi in 2025, will continue new openings in the Seto Inland Sea area, and expects sustained growth driven by government policy shifting care from hospitals to home.

• OLBA-DX and Logistics Innovation

  • The DX Promotion Office (established 2021) is expanding use of generative AI and no-code tools, building CRM/SFA (currently in pilot testing), refreshing groupware and sales management systems, and training DX talent. The integrated logistics system "Li-Flo" will complete full group rollout by the end of FY2025 June, delivering improved inventory, quality, and picking efficiency. Construction of the new Okayama Logistics Center is targeted for launch in July 2027, to serve as a hub for Chugoku-Shikoku region and strengthen BCP and stable supply.

• New Business Development

  • Temasack, the automatic checkout machine for clinics, has sold 255 units in the past year with a cumulative 754 units installed, with 40% of sales in the Kanto region and sales footprint in 46 prefectures. The 100% owned subsidiary Olseed was established in January 2025 to sell the low-temperature pyrolysis upcycling unit OLSTECH, which reduces CO2 emissions and already has initial sales 6 months after founding. The newborn live streaming and memorial movie service Babyeets for obstetrics and gynecology departments has completed installation at 2 facilities as of FY2025 June. For the Thai Olba Healthcare joint venture (founded 2023), the company completed delivery of the first automatic tablet packing machine to a university hospital and is preparing delivery of a second unit, with sales preparation ongoing for rehabilitation equipment and Thai orthopedic implants, targeting future ASEAN expansion.

• ESG and Human Capital Management

  • The company has maintained its Certified Healthy Company designation, implemented the GLTD long-term disability income coverage system, supports women's career advancement, promotes male parental leave, runs annual engagement surveys, and runs the OLBA Academy structured internal training program to develop employee expertise.

1. Medical Equipment Business (revenue contribution: 93.2%): Revenue of 115.878 billion yen, +3.3% YoY; Operating profit of 1.774 billion yen, -12.9% YoY. Within the segment, consumables total revenue reached 103.4 billion yen, +6.5% YoY (surgical consumables +3.9% YoY, orthopedic consumables +10.6% YoY, cardiovascular consumables +7.2% YoY); capital equipment and supplies revenue reached 14.6 billion yen, -14.5% YoY. 2. SPD Business (revenue contribution: 4.6%): Revenue of 5.717 billion yen, +9.4% YoY; Operating profit of 113 million yen, +9.0% YoY. 3. Nursing Care Products Business (revenue contribution: 2.2%): Revenue of 2.777 billion yen, +5.2% YoY; Operating profit of 205 million yen, -1.8% YoY.

• For FY2026 June, the company forecasts consolidated revenue of 127.978 billion yen (new all-time high, 6th consecutive year of revenue growth), operating profit of 2.0 billion yen (+21 million yen YoY, recovering to the 2 billion yen level after last year's decline), and net profit attributable to parent company shareholders of 1.321 billion yen. The projected net profit decline is a one-time reversal effect from prior year subsidiary head office integration accounting.
• The medium-term management plan covering FY2026 to FY2028 June targets 142 billion yen in consolidated revenue and 2.7 billion yen in operating profit by FY2028 June.
• The long-term VISION2030 targets becoming the top medical equipment trading company in Japan, generating 20% of operating profit from overseas markets, and launching more than 30 new products and services.
• The dividend policy maintains a target of increasing or maintaining dividends, with a planned 80 yen per share dividend for both FY2025 June and FY2026 June. As of FY2025 June end, the company's DOE (dividend on equity) is 4.0% and dividend yield is 4.0%, both relatively high against industry averages.
• The company aims to increase its PBR above the Standard Market wholesale industry average of 1.2x, driven by improving net profit margin through DX efficiency gains and growing expected growth rate through new business and overseas expansion.

• Global inflation and yen depreciation have driven rising prices for imported medical equipment. The company is negotiating price pass-through to customers while offering alternative products, but input cost pressure remains.
• Weakened hospital capital investment, driven by reduced COVID-19 subsidies, rising labor and resource costs, and deteriorating hospital operating conditions, has led to a sharp decline in medical equipment and supplies sales, and this pressure is expected to continue in the near term.
• The company has two core internal weaknesses: inherent low profit margins typical for the wholesale industry, and low market share in large metropolitan areas. The company is working to address these but geographic expansion and margin improvement carry execution risks.
• Expansion into new businesses and overseas markets is still in early stages, and there is no guarantee that these initiatives will achieve expected sales and profit levels to support long-term growth targets.

No Q&A section was included in the provided transcript.